Pura Vida Investments’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
VA
BI
RSCM
FCMI
CC
Pura Vida Investments's ACRS Position: Q1 2022 in Review
Pura Vida Investments sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 48,266 shares — an estimated $702K sold.
Pura Vida Investments first reported a position in ACRS in Q4 2020 and held it in 3 quarters. The position peaked at $4.43M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.
- Pura Vida Investments reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
- Pura Vida Investments sold 48,266 Aclaris Therapeutics shares in Q1 2022, an estimated $702K.
- Pura Vida Investments first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 3 quarters.
- Pura Vida Investments's Aclaris Therapeutics position peaked at $4.43M in Q1 2021.
- 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.
Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.